The role of stereotactic body radiation therapy in the treatment of colorectal liver metastases

  • Mladen Marinkovic Clinic for Radiation Oncology and Diagnostics, Department of Radiation Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
  • Suzana Stojanovic-Rundic Clinic for Radiation Oncology and Diagnostics, Department of Radiation Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia;
DOI: https://doi.org/10.5937/mp73-34773
Keywords: colorectal carcinoma, liver metastases, stereotactic body radiation therapy

Abstract


Colorectal cancer is third most common malignant disease and second leading cause of cancer-related deaths worldwide. In Serbia in 2020 there were 5900 new cases and around 3300 number of deaths related to this disease. Metastatic disease is most frequently located in liver.  Surgery is first option if complete resection of liver metastases is achievable. Since liver metastases are resectable in 10-20% of cases there is a possibility of implementation of other treatment modality. Alteranative for surgery in local treatment of unresectable metastases are stereotactic body radiation therapy (SBRT), interstitial and intraluminal brachytherapy, transarterial chemoembolization, hepatic arterial infusion chemotherapy, selective internal radiation therapy with yttrium-90 resin microspheres, cryoablation, radiofrequency , chemical, and microwave ablation. Candidates for SBRT are patients with unresectable liver metastatic disease and patients with comorbidities which disable surgical treatment, with adequate function of uninvolved liver tissue. Respiration induced motion of target volume can be reduced by indroduction of motion management strategies such as infrared markers, deep inspiration breath hold, abdominal compression, respiratory tracking and gating. CyberKnife, TomoTherapy machine and modified linear accelerators are used for delivering SBRT. These units allow us to deliver dose more precisely and to make dose escalation. Different regimes of fractionation are optional, from single fraction to hypofractionation regimes, and doses are typically around 30–60 Gy in 3 fractions. Low toxicity rates in patients with liver metastases treated with SBRT are in relation with precise treatment planning, dose prescription and fractionation. Results of research suggest that delivery of large doses can provide high rate of local response, but on the other hand there is possibility of disease progression out of target volumes. With adequate selection of patients with unresectable liver metastases, the implementation of SBRT, especially in combination with effective systematic treatment modalities, can provide better local control with extension of survival.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021 May 1;71(3):209–49. Available from: https://doi.org/10.3322/caac.21660
2. Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol. 2007 Feb;14(2):766–70.
3. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986 Nov;150(3):195–203.
4. Tsai M-S, Su Y-H, Ho M-C, Liang J-T, Chen T-P, Lai H-S, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol. 2007 Feb;14(2):786–94.
5. Choti MA, Sitzmann J V, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002 Jun;235(6):759–66.
6. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1208–15.
7. Rocha FG, Helton WS. Resectability of colorectal liver metastases: an evolving definition. HPB (Oxford) [Internet]. 2012/03/19. 2012 May;14(5):283–4. Available from: https://pubmed.ncbi.nlm.nih.gov/22487064
8. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Jul;23(20):4553–60.
9. van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016 May;34(15):1723–31.
10. Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, et al. DEB-TACE: a standard review. Future Oncol. 2018 Dec;14(28):2969–84.
11. Xing M, Kooby DA, El-Rayes BF, Kokabi N, Camacho JC, Kim HS. Locoregional therapies for metastatic colorectal carcinoma to the liver--an evidence-based review. J Surg Oncol. 2014 Aug;110(2):182–96.
12. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009 May;19(5):1206–13.
13. Lim A, Le Sourd S, Senellart H, Luet D, Douane F, Perret C, et al. Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study. Clin Colorectal Cancer. 2017 Dec;16(4):308–15.
14. Edyta W-R, Jakub L, Jerzy W. Whole Liver Palliative Radiotherapy for Patients with Massive Liver Metastases. Asian Pac J Cancer Prev. 2015;16(15):6381–4.
15. Austin-Seymour MM, Chen GT, Castro JR, Saunders WM, Pitluck S, Woodruff KH, et al. Dose volume histogram analysis of liver radiation tolerance. Int J Radiat Oncol Biol Phys. 1986 Jan;12(1):31–5.
16. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995 Mar;31(5):1237–48.
17. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991 May;21(1):109–22.
18. McPartlin A, Swaminath A, Wang R, Pintilie M, Brierley J, Kim J, et al. Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases. Int J Radiat Oncol Biol Phys. 2017 Oct;99(2):388–95.
19. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.
20. Tanaka O, Kojima T, Ohbora A, Makita C, Taniguchi T, Ono K, et al. Scores of Child-Pugh Classification Impact Overall Survival After Stereotactic Body Radiation Therapy for Primary and Metastatic Liver Tumors. J Clin Exp Hepatol [Internet]. 2019/05/21. 2020;10(2):101–5. Available from: https://pubmed.ncbi.nlm.nih.gov/32189924
21. Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013 Jun;86(2):336–42.
22. Wulf J, Hädinger U, Oppitz U, Thiele W, Ness-Dourdoumas R, Flentje M. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol. 2001 Dec;177(12):645–55.
23. K.A. G. Stereotactic Radiosurgery for Liver Malignancies Using the CyberKnife. Urschel Jr HC, editor. Heidelburg: Springer; 2007. 217–25 p.
24. Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005 Oct;15(4):279–83.
25. Schefter TE, Kavanagh BD. Radiation therapy for liver metastases. Semin Radiat Oncol. 2011 Oct;21(4):264–70.
26. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010 Oct;78(2):486–93.
27. Meyer JJ, Foster RD, Lev-Cohain N, Yokoo T, Dong Y, Schwarz RE, et al. A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases. Ann Surg Oncol. 2016 Jan;23(1):218–24.
28. Kok END, Jansen EPM, Heeres BC, Kok NFM, Janssen T, van Werkhoven E, et al. High versus low dose Stereotactic Body Radiation Therapy for hepatic metastases. Clin Transl Radiat Oncol. 2020 Jan;20:45–50.
29. Heinzerling JH, Anderson JF, Papiez L, Boike T, Chien S, Zhang G, et al. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys. 2008 Apr;70(5):1571–8.
30. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011 Sep;117(17):4060–9.
31. Scorsetti M, Comito T, Clerici E, Franzese C, Tozzi A, Iftode C, et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiat Oncol. 2018 Nov;13(1):234.
32. Mahadevan A, Blanck O, Lanciano R, Peddada A, Sundararaman S, D’Ambrosio D, et al. Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol [Internet]. 2018 Feb 13;13(1):26. Available from: https://pubmed.ncbi.nlm.nih.gov/29439707
33. Sorafenib-RT Treatment for Liver Metastasis (SLIM). ClinicalTrials.gov.NCT0089242. Last Uptated: September 10, 2020.
Published
2022/04/07
Issue
Vol. 73 No. 1 (2022): Medicinski podmladak
Section
Mini pregledni članak